Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Zelicapavir by Enanta Pharmaceuticals for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
Zelicapavir is under clinical development by Enanta Pharmaceuticals and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections. According...
Data Insights
Risk adjusted net present value: What is the current valuation of Enanta Pharmaceuticals's Zelicapavir?
Zelicapavir is a small molecule commercialized by Enanta Pharmaceuticals, with a leading Phase II program in Respiratory Syncytial Virus (RSV)...